(Q57830334)

English

Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning

article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

1 reference

based on heuristic

inferred from title

author name string

Marta Cremonesi

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Mahila Esmeralda Ferrari

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Carlo Chiesa

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Anna Sarnelli

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Cristina Garibaldi

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Massimiliano Pacilio

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Lidia Strigari

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Roberto Orecchia

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Chiara Maria Grana

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Francesca Botta

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

publication date

21 May 2018

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

number of pages

16

1 reference

based on heuristic

inferred from page(s)

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

45

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

2426-2441

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Tolerance of normal tissue to therapeutic irradiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-rate effects in targeted radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

End-stage renal disease after treatment with 90Y-DOTATOC.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dosimetry in Peptide radionuclide receptor therapy: a review.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dosimetry for treatment with radiolabelled somatostatin analogues. A review.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of normal tissue complication probability models in the clinic

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiation-associated kidney injury.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

4D SPECT/CT acquisition for 3D dose calculation and dose planning in (177)Lu-peptide receptor radionuclide therapy: applications for clinical routine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose?

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single centre experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: the experience of Busto Arsizio Hospital (Italy).

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with 177Lu-DOTATATE.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kidney dosimetry in ¹⁷⁷Lu and ⁹⁰Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiation exposure of the spleen during (177)Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel planar image-based method for bone marrow dosimetry in (177)Lu-DOTATATE treatment correlates with haematological toxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy-related hematological malignancies after peptide receptor radionuclide therapy with (177)Lu-DOTA-Octreotate: Incidence, course & predicting factors in patients with GEP-NETs

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-018-4044-X

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57830334&oldid=2249122456"